Impact BioMedical, INC. Financing Cash Flow
Impact BioMedical, INC. (IBO) reported Financing Cash Flow of $482.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-05-12
- Impact BioMedical, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $482.00K.
- Impact BioMedical, INC. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $317.00K, a 36.64% increase year-over-year.
- Impact BioMedical, INC. net cash provided by (used in) financing activities for the quarter ending 2024-09-30 was $3.67M, a 321.38% increase year-over-year.
- Impact BioMedical, INC. net cash provided by (used in) financing activities for the quarter ending 2024-06-30 was $384.00K, a 48.53% decline year-over-year.
- Impact BioMedical, INC. net cash provided by (used in) financing activities for fiscal 2025 was -$109.00K, a 102.25% decline from fiscal 2024.
- Impact BioMedical, INC. net cash provided by (used in) financing activities for fiscal 2024 was $4.85M, a 69.28% increase from fiscal 2023.
- Impact BioMedical, INC. net cash provided by (used in) financing activities for fiscal 2023 was $2.87M, a 12.49% increase from fiscal 2022.
- Impact BioMedical, INC. net cash provided by (used in) financing activities for fiscal 2022 was $2.55M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $482.00K 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | -$109.00K 10-K · filed 2026-03-11 | |||||||
| 2024-12-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.98M derived: sum of 2 quarters · filed 2026-03-11 | $4.37M derived: sum of 3 quarters · filed 2026-03-11 | $4.85M 10-K · filed 2026-03-11 | $5.92M 10-K · filed 2025-03-28 | |||
| 2024-09-30 | $3.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $4.05M derived: sum of 2 quarters · filed 2025-11-07 | $4.53M 10-Q · filed 2025-11-07 | $5.33M 10-Q · filed 2024-11-12 | $4.76M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $384.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $867.00K 10-Q · filed 2025-08-14 | $1.38M 10-Q · filed 2024-08-13 | $1.10M derived: sum of 3 quarters · filed 2025-08-14 | $1.97M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $483.00K 10-Q · filed 2025-05-14 | $713.00K 10-Q · filed 2024-05-10 | $715.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.58M derived: sum of 3 quarters · filed 2025-05-14 | $2.33M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $232.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.10M derived: sum of 2 quarters · filed 2025-03-28 | $1.85M derived: sum of 3 quarters · filed 2025-03-28 | $2.87M 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | $870.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.62M derived: sum of 2 quarters · filed 2024-11-12 | $2.63M 10-Q · filed 2024-11-12 | $3.17M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.76M 10-Q · filed 2024-08-13 | $2.30M derived: sum of 3 quarters · filed 2024-08-13 | $3.08M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $1.02M 10-Q · filed 2024-05-10 | $1.56M derived: sum of 2 quarters · filed 2024-05-10 | $2.33M derived: sum of 3 quarters · filed 2024-05-10 | |||||
| 2022-12-31 | $539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.31M derived: sum of 2 quarters · filed 2024-02-20 | $2.55M 10-K · filed 2024-02-20 | |||||
| 2022-09-30 | $773.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.01M 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | $1.24M 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |